Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season
•Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza B.•Infants showed no significant vaccine effectiveness.•The children who were immunized in two consecutive seasons were more likely to have influenz...
Saved in:
Published in | Vaccine Vol. 36; no. 37; pp. 5510 - 5518 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
05.09.2018
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza B.•Infants showed no significant vaccine effectiveness.•The children who were immunized in two consecutive seasons were more likely to have influenza.•However, the influenza vaccine should be recommended every season for children.
We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.
Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.
During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.
VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children. |
---|---|
AbstractList | •Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza B.•Infants showed no significant vaccine effectiveness.•The children who were immunized in two consecutive seasons were more likely to have influenza.•However, the influenza vaccine should be recommended every season for children.
We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.
Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.
During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.
VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.OBJECTIVESWe assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.METHODSOur study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29-46) against influenza A and 39% (95% CI, 18-54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05-2.38], adjusted odds ratio, 1.53 [95% CI, 0.99-2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.RESULTSDuring the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29-46) against influenza A and 39% (95% CI, 18-54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05-2.38], adjusted odds ratio, 1.53 [95% CI, 0.99-2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.CONCLUSIONSVE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE. Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination. During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29-46) against influenza A and 39% (95% CI, 18-54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05-2.38], adjusted odds ratio, 1.53 [95% CI, 0.99-2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season. VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children. Highlights•Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2). •Vaccine was effective in preventing illness, 39% against influenza B. •Infants showed no significant vaccine effectiveness. •The children who were immunized in two consecutive seasons were more likely to have influenza. •However, the influenza vaccine should be recommended every season for children. ObjectivesWe assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.MethodsOur study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.ResultsDuring the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.ConclusionsVE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children. |
Author | Iibuchi, Noriko Mitamura, Keiko Munenaga, Takeshi Tamaoka, Satoshi Sugaya, Norio Kobayashi, Hisato Yamaguchi, Yoshio Shibata, Meiwa Goto, Anna Kobayashi, Yasuaki Nakata, Yuji Takahashi, Takao Kamimaki, Isamu Nishida, Mitsuhiro Shinjoh, Masayoshi Hirano, Yasuhiro Narabayashi, Atsushi Morita, Kumiko |
Author_xml | – sequence: 1 givenname: Masayoshi surname: Shinjoh fullname: Shinjoh, Masayoshi organization: Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan – sequence: 2 givenname: Norio surname: Sugaya fullname: Sugaya, Norio email: sugaya-n@za2.so-net.ne.jp organization: Department of Pediatrics, Keiyu Hospital, Yokohama, Kanagawa, Japan – sequence: 3 givenname: Yoshio surname: Yamaguchi fullname: Yamaguchi, Yoshio organization: Institute of Clinical Research Department of Infection & Allergy, National Hospital Organization Tochigi Medical Center, Utsunomiya, Tochigi, Japan – sequence: 4 givenname: Noriko surname: Iibuchi fullname: Iibuchi, Noriko organization: Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan – sequence: 5 givenname: Isamu surname: Kamimaki fullname: Kamimaki, Isamu organization: Department of Pediatrics, National Hospital Organization Saitama National Hospital, Wako, Saitama, Japan – sequence: 6 givenname: Anna surname: Goto fullname: Goto, Anna organization: Department of Pediatrics, Ota Memorial Hospital, Ota, Gunma, Japan – sequence: 7 givenname: Hisato surname: Kobayashi fullname: Kobayashi, Hisato organization: Department of Pediatrics, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan – sequence: 8 givenname: Yasuaki surname: Kobayashi fullname: Kobayashi, Yasuaki organization: Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, Ashikaga, Tochigi, Japan – sequence: 9 givenname: Meiwa surname: Shibata fullname: Shibata, Meiwa organization: Division of Pediatrics, Yokohama Rosai Hospital, Yokohama, Japan – sequence: 10 givenname: Satoshi surname: Tamaoka fullname: Tamaoka, Satoshi organization: Department of Pediatrics, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochgi, Japan – sequence: 11 givenname: Yuji surname: Nakata fullname: Nakata, Yuji organization: Department of Pediatrics, Nippon Kokan Hospital, Kawasaki, Kanagawa, Japan – sequence: 12 givenname: Atsushi surname: Narabayashi fullname: Narabayashi, Atsushi organization: Kawasaki Municipal Kawasaki Hospital, Kawasaki, Kanagawa, Japan – sequence: 13 givenname: Mitsuhiro surname: Nishida fullname: Nishida, Mitsuhiro organization: Department of Pediatrics, Shizuoka City Shimizu Hospital, Shizuoka, Japan – sequence: 14 givenname: Yasuhiro surname: Hirano fullname: Hirano, Yasuhiro organization: Department of Pediatrics, Hiratsuka City Hospital, Hiratsuka, Kanagawa, Japan – sequence: 15 givenname: Takeshi surname: Munenaga fullname: Munenaga, Takeshi organization: Department of Pediatrics, Ota Memorial Hospital, Ota, Gunma, Japan – sequence: 16 givenname: Kumiko surname: Morita fullname: Morita, Kumiko organization: Department of Pediatrics, Hiratsuka City Hospital, Hiratsuka, Kanagawa, Japan – sequence: 17 givenname: Keiko surname: Mitamura fullname: Mitamura, Keiko organization: Department of Pediatrics, Eiju General Hospital, Tokyo, Japan – sequence: 18 givenname: Takao surname: Takahashi fullname: Takahashi, Takao organization: Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30093289$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkl2LEzEUhoOsuB_6E5SAN960npPJTDKIiix-LCx4oYJ3Ic2ccVOnmW4yU-j-ejPbuhcFqZCQkDzvy-G855ydhD4QY88R5ghYvV7ON9Y5H2guAPUc1Byq8hE7Q62KmShRn7AzEJWcSYSfp-w8pSUAlAXWT9hpAVAXQtdn7O4qWDf4jR2o4T603UjhzvK9N6e2pembAqXEbWjyzst22-QT71seaU332p3CDr4PvO0jdze-ayIF3ozRh198uCEupsJR8UQ29eEpe9zaLtGz_XnBfnz6-P3yy-z66-eryw_XM1cBDjOrWtUoKYXEAtC5hSiUq4UuZVUtZGnb_FCDynfboHS6KBGhlbqqXaO1q4sL9mrnu4797UhpMCufHHWdDdSPyQjEqhZSCXkcBa1KXReyzOjLA3TZjzF3ZqJqKbRWoDL1Yk-NixU1Zh39ysat-RtABsod4GKfUqT2AUEwU9BmafZhmCloA8rkoLPuzYHO-eG--0O0vjuqfr9TU-77xlM0yXkKjhofc96m6f1Rh3cHDq7zwTvb_aYtpYdeoEnCgPk2jeI0iagLBCUhG7z9t8F_FPAHbC3vTA |
CitedBy_id | crossref_primary_10_1097_EDE_0000000000001116 crossref_primary_10_1016_j_vaccine_2019_05_090 crossref_primary_10_1272_jnms_JNMS_2022_89_102 crossref_primary_10_1038_s41541_019_0123_7 crossref_primary_10_3390_vaccines7020053 crossref_primary_10_3390_v11090868 crossref_primary_10_1186_s12879_022_07898_y crossref_primary_10_1016_j_vaccine_2022_03_047 crossref_primary_10_1007_s00705_024_06210_4 crossref_primary_10_1371_journal_pone_0249005 crossref_primary_10_3389_fimmu_2020_568978 crossref_primary_10_1016_j_vaccine_2024_02_006 crossref_primary_10_1017_S0950268820002058 crossref_primary_10_1016_j_vaccine_2022_07_002 crossref_primary_10_1016_j_vaccine_2024_126241 crossref_primary_10_3390_vaccines9121447 crossref_primary_10_1080_21645515_2019_1677438 crossref_primary_10_1080_14760584_2020_1711056 crossref_primary_10_37191_Mapsci_2582_4333_3_5__085 crossref_primary_10_1016_j_vaccine_2020_02_049 crossref_primary_10_1093_infdis_jiz434 crossref_primary_10_1080_21645515_2025_2468074 crossref_primary_10_1016_j_jiac_2021_08_020 crossref_primary_10_1016_j_vaccine_2024_05_034 crossref_primary_10_1016_S2213_2600_22_00266_1 crossref_primary_10_1371_journal_pone_0256165 crossref_primary_10_1016_j_jiac_2024_06_023 crossref_primary_10_1016_S1245_1789_23_48777_X crossref_primary_10_3390_ijerph16061078 crossref_primary_10_1016_j_vaccine_2022_04_033 |
Cites_doi | 10.1093/cid/ciu680 10.1093/cid/cix209 10.1371/journal.pone.0136539 10.7326/M17-0848 10.1016/j.jinf.2011.06.008 10.1093/infdis/jit091 10.1093/infdis/jix055 10.1371/journal.pone.0088813 10.1080/14760584.2017.1334554 10.1016/j.vaccine.2018.01.024 10.2807/1560-7917.ES.2016.21.42.30377 10.1111/irv.12565 10.1038/s41598-017-14536-0 10.1007/s10156-011-0288-0 10.1093/infdis/jiy027 10.2807/1560-7917.ES.2017.22.44.17-00306 10.1186/s12916-017-0919-0 10.15585/mmwr.rr6602a1 10.1093/cid/cix461 10.1093/infdis/jit263 10.2807/1560-7917.ES.2017.22.7.30464 10.15585/mmwr.mm6606a3 10.2807/1560-7917.ES.2016.21.7.30139 10.1093/cid/ciw176 |
ContentType | Journal Article |
Copyright | 2018 Copyright © 2018. Published by Elsevier Ltd. Copyright Elsevier Limited Sep 5, 2018 |
Copyright_xml | – notice: 2018 – notice: Copyright © 2018. Published by Elsevier Ltd. – notice: Copyright Elsevier Limited Sep 5, 2018 |
CorporateAuthor | on behalf of the Keio Pediatric Influenza Research Group Keio Pediatric Influenza Research Group |
CorporateAuthor_xml | – name: on behalf of the Keio Pediatric Influenza Research Group – name: Keio Pediatric Influenza Research Group |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
DOI | 10.1016/j.vaccine.2018.07.065 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection Proquest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AGRICOLA Research Library Prep |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 5518 |
ExternalDocumentID | 30093289 10_1016_j_vaccine_2018_07_065 S0264410X18310740 1_s2_0_S0264410X18310740 |
Genre | Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU EFLBG LCYCR QYZTP AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c601t-a7f7d744241301ccb237c9285466b45afb239076b4ad14c835110f4869cd88c93 |
IEDL.DBID | 7X7 |
ISSN | 0264-410X 1873-2518 |
IngestDate | Thu Jul 10 18:51:28 EDT 2025 Tue Aug 05 11:01:16 EDT 2025 Wed Aug 13 08:07:29 EDT 2025 Mon Jul 21 05:59:16 EDT 2025 Tue Jul 01 01:06:42 EDT 2025 Thu Apr 24 23:08:33 EDT 2025 Fri Feb 23 02:47:37 EST 2024 Sun Feb 23 10:19:35 EST 2025 Tue Aug 26 16:40:39 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 37 |
Keywords | Hospitalization Repeated vaccination Effectiveness Children Test-negative case control design Influenza vaccine |
Language | English |
License | Copyright © 2018. Published by Elsevier Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c601t-a7f7d744241301ccb237c9285466b45afb239076b4ad14c835110f4869cd88c93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 30093289 |
PQID | 2094288707 |
PQPubID | 105530 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2116924724 proquest_miscellaneous_2087589345 proquest_journals_2094288707 pubmed_primary_30093289 crossref_primary_10_1016_j_vaccine_2018_07_065 crossref_citationtrail_10_1016_j_vaccine_2018_07_065 elsevier_sciencedirect_doi_10_1016_j_vaccine_2018_07_065 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X18310740 elsevier_clinicalkey_doi_10_1016_j_vaccine_2018_07_065 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-09-05 |
PublicationDateYYYYMMDD | 2018-09-05 |
PublicationDate_xml | – month: 09 year: 2018 text: 2018-09-05 day: 05 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2018 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Martinez-Baz, Casado, Navascues, Diaz-Gonzalez, Aguinaga, Barrado (b0095) 2017; 215 WHO. Influenza Laboratory Surveillance Information. Data source: FluNet Belongia, Skowronski, McLean, Chambers, Sundaram, De Serres (b0085) 2017; 16 Sakai-Tagawa, Yamayoshi, Kawakami, Le, Uchida, Saito (b0105) 2017; 7 The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan [In Japanese]. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016;21:pii=30139. Sugaya, Shinjoh, Kawakami, Yamaguchi, Yoshida, Baba (b0040) 2016; 21 Merckx, Wali, Schiller, Caya, Gore, Chartrand (b0140) 2017; 167 WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS) Global Influenza Surveillance and Response System (GISRS) Grohskopf, Sokolow, Broder, Walter, Bresee, Fry (b0065) 2017; 66 McLean, Thompson, Sundaram, Meece, McClure, Friedrich (b0080) 2014; 59 Ramsay, Buchan, Stirling, Cowling, Feng, Kwong (b0100) 2017; 15 Chiu, Kwan, Feng, Wong, Leung, Chan (b0135) 2018 2017. Suzuki, Minh le, Yoshimine, Inoue, Yoshida, Morimoto (b0145) 2014; 9 Skowronski, Chambers, Sabaiduc, De Serres, Winter, Dickinson (b0075) 2016; 63 Flannery, Chung, Thaker, Monto, Martin, Belongia (b0025) 2017; 66 FluNet; 2017. CDC. Vaccine effectiveness – how well does the flu vaccine work? Cheng, Macartney, Waterer, Kotsimbos, Kelly, Blyth (b0090) 2017; 64 Sugaya, Shinjoh, Mitamura, Takahashi (b0050) 2011; 63 Sugaya, Shinjoh, Nakata, Tsunematsu, Yamaguchi, Komiyama (b0045) 2018; 36 Domachowske, Pankow-Culot, Bautista, Feng, Claeys, Peeters (b0115) 2013; 207 The National Institute of Infectious Diseases. Influenza vaccine coverage rate by age and age group, Japan [In Japanese]. The National Institute of Infectious Diseases N. Influenza virus isolation, 2013/14-2017/18, Japan [In Japanese]. The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan. . Langley, Carmona Martinez, Chatterjee, Halperin, McNeil, Reisinger (b0120) 2013; 208 Shinjoh, Sugaya, Yamaguchi, Tomidokoro, Sekiguchi, Mitamura (b0035) 2015; 10 Pebody, Warburton, Ellis, Andrews, Potts, Cottrell (b0030) 2017; 22 Kissling, Rondy (b0110) 2017; 22 Sugaya (b0055) 2011; 17 Bruning, Leeflang, Vos, Spijker, de Jong, Wolthers (b0150) 2017; 65 2018. Suzuki (10.1016/j.vaccine.2018.07.065_b0145) 2014; 9 Sugaya (10.1016/j.vaccine.2018.07.065_b0055) 2011; 17 10.1016/j.vaccine.2018.07.065_b0005 McLean (10.1016/j.vaccine.2018.07.065_b0080) 2014; 59 Martinez-Baz (10.1016/j.vaccine.2018.07.065_b0095) 2017; 215 Sugaya (10.1016/j.vaccine.2018.07.065_b0045) 2018; 36 Cheng (10.1016/j.vaccine.2018.07.065_b0090) 2017; 64 Shinjoh (10.1016/j.vaccine.2018.07.065_b0035) 2015; 10 Langley (10.1016/j.vaccine.2018.07.065_b0120) 2013; 208 Merckx (10.1016/j.vaccine.2018.07.065_b0140) 2017; 167 Ramsay (10.1016/j.vaccine.2018.07.065_b0100) 2017; 15 10.1016/j.vaccine.2018.07.065_b0070 10.1016/j.vaccine.2018.07.065_b0010 Belongia (10.1016/j.vaccine.2018.07.065_b0085) 2017; 16 Skowronski (10.1016/j.vaccine.2018.07.065_b0075) 2016; 63 Kissling (10.1016/j.vaccine.2018.07.065_b0110) 2017; 22 10.1016/j.vaccine.2018.07.065_b0015 10.1016/j.vaccine.2018.07.065_b0155 Sugaya (10.1016/j.vaccine.2018.07.065_b0040) 2016; 21 Bruning (10.1016/j.vaccine.2018.07.065_b0150) 2017; 65 Chiu (10.1016/j.vaccine.2018.07.065_b0135) 2018 Pebody (10.1016/j.vaccine.2018.07.065_b0030) 2017; 22 Sakai-Tagawa (10.1016/j.vaccine.2018.07.065_b0105) 2017; 7 Flannery (10.1016/j.vaccine.2018.07.065_b0025) 2017; 66 Sugaya (10.1016/j.vaccine.2018.07.065_b0050) 2011; 63 10.1016/j.vaccine.2018.07.065_b0060 Grohskopf (10.1016/j.vaccine.2018.07.065_b0065) 2017; 66 10.1016/j.vaccine.2018.07.065_b0020 Domachowske (10.1016/j.vaccine.2018.07.065_b0115) 2013; 207 10.1016/j.vaccine.2018.07.065_b0125 |
References_xml | – reference: WHO. Influenza Laboratory Surveillance Information. Data source: FluNet ( – reference: ), Global Influenza Surveillance and Response System (GISRS) – reference: Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016;21:pii=30139. – reference: The National Institute of Infectious Diseases. Influenza vaccine coverage rate by age and age group, Japan [In Japanese]. – volume: 66 start-page: 167 year: 2017 end-page: 171 ident: b0025 article-title: Interim estimates of 2016–17 seasonal influenza vaccine effectiveness – United States, February 2017 publication-title: MMWR Morb Mortal Wkly Rep – volume: 215 start-page: 847 year: 2017 end-page: 855 ident: b0095 article-title: Effect of repeated vaccination with the same vaccine component against 2009 pandemic influenza A(H1N1) virus publication-title: J Infect Dis – volume: 10 start-page: e0136539 year: 2015 ident: b0035 article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results publication-title: PLoS One – volume: 65 start-page: 1026 year: 2017 end-page: 1032 ident: b0150 article-title: Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis publication-title: Clin Infect Dis – volume: 16 start-page: 1 year: 2017 end-page: 14 ident: b0085 article-title: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence publication-title: Expert Rev Vaccines – reference: The National Institute of Infectious Diseases N. Influenza virus isolation, 2013/14-2017/18, Japan [In Japanese]. – volume: 36 start-page: 1063 year: 2018 end-page: 1071 ident: b0045 article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016 publication-title: Vaccine – reference: The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan. – volume: 207 start-page: 1878 year: 2013 end-page: 1887 ident: b0115 article-title: A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years publication-title: J Infect Dis – volume: 208 start-page: 544 year: 2013 end-page: 553 ident: b0120 article-title: Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children publication-title: J Infect Dis – volume: 9 start-page: e88813 year: 2014 ident: b0145 article-title: Vaccine effectiveness against medically attended laboratory-confirmed influenza in Japan, 2011–2012 season publication-title: PLoS One – volume: 15 start-page: 159 year: 2017 ident: b0100 article-title: The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis publication-title: BMC Med – reference: . FluNet; 2017. – volume: 66 start-page: 1 year: 2017 end-page: 20 ident: b0065 article-title: Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2017–18 Influenza Season publication-title: MMWR Recomm Rep – volume: 22 year: 2017 ident: b0110 article-title: Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe publication-title: Euro Surveill – reference: WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS) – volume: 63 start-page: 288 year: 2011 end-page: 294 ident: b0050 article-title: Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children publication-title: J Infect – volume: 17 start-page: 595 year: 2011 end-page: 601 ident: b0055 article-title: Widespread use of neuraminidase inhibitors in Japan publication-title: J Infect Chemother – reference: . 2018. – reference: CDC. Vaccine effectiveness – how well does the flu vaccine work? – volume: 7 start-page: 14483 year: 2017 ident: b0105 article-title: Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan publication-title: Sci Rep – reference: ; 2017. – reference: The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan [In Japanese]. – volume: 64 start-page: 1564 year: 2017 end-page: 1572 ident: b0090 article-title: Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza publication-title: Clin Infect Dis – reference: . – volume: 21 year: 2016 ident: b0040 article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan publication-title: Euro Surveill – volume: 63 start-page: 21 year: 2016 end-page: 32 ident: b0075 article-title: A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 Season publication-title: Clin Infect Dis – volume: 167 start-page: 394 year: 2017 end-page: 409 ident: b0140 article-title: diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis publication-title: Ann Intern Med – year: 2018 ident: b0135 article-title: Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17 publication-title: J Infect Dis – volume: 59 start-page: 1375 year: 2014 end-page: 1385 ident: b0080 article-title: Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons publication-title: Clin Infect Dis – volume: 22 year: 2017 ident: b0030 article-title: End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17 publication-title: Euro Surveill – volume: 59 start-page: 1375 year: 2014 ident: 10.1016/j.vaccine.2018.07.065_b0080 article-title: Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons publication-title: Clin Infect Dis doi: 10.1093/cid/ciu680 – ident: 10.1016/j.vaccine.2018.07.065_b0155 – volume: 64 start-page: 1564 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0090 article-title: Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza publication-title: Clin Infect Dis doi: 10.1093/cid/cix209 – volume: 10 start-page: e0136539 year: 2015 ident: 10.1016/j.vaccine.2018.07.065_b0035 article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results publication-title: PLoS One doi: 10.1371/journal.pone.0136539 – volume: 167 start-page: 394 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0140 article-title: diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/M17-0848 – volume: 63 start-page: 288 year: 2011 ident: 10.1016/j.vaccine.2018.07.065_b0050 article-title: Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children publication-title: J Infect doi: 10.1016/j.jinf.2011.06.008 – volume: 207 start-page: 1878 year: 2013 ident: 10.1016/j.vaccine.2018.07.065_b0115 article-title: A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years publication-title: J Infect Dis doi: 10.1093/infdis/jit091 – volume: 215 start-page: 847 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0095 article-title: Effect of repeated vaccination with the same vaccine component against 2009 pandemic influenza A(H1N1) virus publication-title: J Infect Dis doi: 10.1093/infdis/jix055 – ident: 10.1016/j.vaccine.2018.07.065_b0060 – volume: 9 start-page: e88813 year: 2014 ident: 10.1016/j.vaccine.2018.07.065_b0145 article-title: Vaccine effectiveness against medically attended laboratory-confirmed influenza in Japan, 2011–2012 season publication-title: PLoS One doi: 10.1371/journal.pone.0088813 – ident: 10.1016/j.vaccine.2018.07.065_b0005 – volume: 16 start-page: 1 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0085 article-title: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2017.1334554 – volume: 36 start-page: 1063 year: 2018 ident: 10.1016/j.vaccine.2018.07.065_b0045 article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016 publication-title: Vaccine doi: 10.1016/j.vaccine.2018.01.024 – ident: 10.1016/j.vaccine.2018.07.065_b0015 – volume: 21 year: 2016 ident: 10.1016/j.vaccine.2018.07.065_b0040 article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2016.21.42.30377 – ident: 10.1016/j.vaccine.2018.07.065_b0125 – ident: 10.1016/j.vaccine.2018.07.065_b0020 – ident: 10.1016/j.vaccine.2018.07.065_b0010 doi: 10.1111/irv.12565 – volume: 7 start-page: 14483 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0105 article-title: Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan publication-title: Sci Rep doi: 10.1038/s41598-017-14536-0 – volume: 17 start-page: 595 year: 2011 ident: 10.1016/j.vaccine.2018.07.065_b0055 article-title: Widespread use of neuraminidase inhibitors in Japan publication-title: J Infect Chemother doi: 10.1007/s10156-011-0288-0 – year: 2018 ident: 10.1016/j.vaccine.2018.07.065_b0135 article-title: Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17 publication-title: J Infect Dis doi: 10.1093/infdis/jiy027 – volume: 22 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0030 article-title: End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2017.22.44.17-00306 – volume: 15 start-page: 159 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0100 article-title: The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis publication-title: BMC Med doi: 10.1186/s12916-017-0919-0 – volume: 66 start-page: 1 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0065 article-title: Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2017–18 Influenza Season publication-title: MMWR Recomm Rep doi: 10.15585/mmwr.rr6602a1 – volume: 65 start-page: 1026 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0150 article-title: Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis publication-title: Clin Infect Dis doi: 10.1093/cid/cix461 – volume: 208 start-page: 544 year: 2013 ident: 10.1016/j.vaccine.2018.07.065_b0120 article-title: Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children publication-title: J Infect Dis doi: 10.1093/infdis/jit263 – volume: 22 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0110 article-title: Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2017.22.7.30464 – volume: 66 start-page: 167 year: 2017 ident: 10.1016/j.vaccine.2018.07.065_b0025 article-title: Interim estimates of 2016–17 seasonal influenza vaccine effectiveness – United States, February 2017 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6606a3 – ident: 10.1016/j.vaccine.2018.07.065_b0070 doi: 10.2807/1560-7917.ES.2016.21.7.30139 – volume: 63 start-page: 21 year: 2016 ident: 10.1016/j.vaccine.2018.07.065_b0075 article-title: A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 Season publication-title: Clin Infect Dis doi: 10.1093/cid/ciw176 |
SSID | ssj0005319 |
Score | 2.4175932 |
Snippet | •Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza... Highlights•Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2). •Vaccine was effective in preventing illness, 39% against... We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In... ObjectivesWe assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season.... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5510 |
SubjectTerms | Adolescent Age Allergy and Immunology Case-Control Studies Child Child, Preschool Children Children & youth Diagnostic systems Effectiveness Enrollments Female Hospitalization Hospitalization - statistics & numerical data Humans Immunity Immunization Infant Infants Influenza Influenza A Influenza A Virus, H3N2 Subtype Influenza B Influenza B virus Influenza vaccine influenza vaccines Influenza Vaccines - therapeutic use Influenza, Human - prevention & control Japan Male Maternal & child health Odds Ratio Patients Repeated vaccination Seasons Test-negative case control design Vaccination Vaccine efficacy Vaccines Vaccines, Inactivated - therapeutic use Viral infections |
SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED9KYWMvY8u-vHZFg9GnOpFtWZIfR1lpBx2FtSNvwpZtSBlOaNJC-7C_vXeS7HS0W8cggcTRYUd3vruf7wvgU1GndalrRCdZ2sZCWR4XvFYIVYqiqXIrlAsXHH-Th2fi6zSfbsB-XwtDaZVB93ud7rR1ODIJuzlZzGaT79zZcj5NaFaWEoTbhVAk5eNfd9I8MjfcgxbHtHpdxTM5H1-VlsLXlOGlXQ9PsjEP26c_-Z_ODh28gOfBgWSf_TW-hI2mG8ETP1LyegRPj0OwfAS7J74t9fUeO11XWS332C47WTesRprRD8qJcYW5rCd_BTdHHRU9XKEzWrOZn2VyU7LwZ5hPBAm6kpVdjW98-RYnbN6yi2bROFpP4SSAoYvM-vpx5kskGbqgLKWdShSjR5bz7jWcHXw53T-Mw6SG2CKgW8WlalWthHBBusTaKs2ULag4U8pK5GWLBxCF4-eyToTVFL3krdCysLXWtsjewGY375p3wCQyHpEy16Ii5aK1pFCzyBurq0SqNgLR88fY0Macpmn8NH2-2rkJO2GIrYYrg2yNYDyQLXwfj8cIZM980xepolo1aGkeI1QPETbLoByWJjHL1HBzT4Aj0APlb_fAv5x0u5dPM5wnReieohHhKoKPw8-oPigmVHbN_JLWIGBFn1Xkf1mTJBJhukpFBG-97A97mNEjMQTt7___2rfgGX1ziXv5NmyuLi6bD-jpraoddyvfAtWuT44 priority: 102 providerName: Elsevier |
Title | Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X18310740 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X18310740 https://dx.doi.org/10.1016/j.vaccine.2018.07.065 https://www.ncbi.nlm.nih.gov/pubmed/30093289 https://www.proquest.com/docview/2094288707 https://www.proquest.com/docview/2087589345 https://www.proquest.com/docview/2116924724 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZoKxAXBMsrUCojoZ6aJU6c2DmhUrXagrpaQYv2ZiV2IlGhZGm2ldoDv50Z20kupUXaR7SbUR7jjL_P8yLkQ25iU0gD7CSJ65ALHYV5ZARQlTyvylRzYd0FJ_Nsdsa_LNOlX3DrfFhlbxOtoTatxjVyIOk5IGUYXeLT6neIXaPQu-pbaGyQLSxdhqNaLMUY4pHYxh5AM3jIWbQcM3g-nk-vCo2ua4zukrZ-J84vt89N_8Kedg46ekqeePBI9522n5EHVTMhD107yesJeXTiHeUTsrtwJamv9-jpmGHV7dFduhiLVYPM5AfGw9ikXNqLPyc3xw0mPFwBEDX0p-tjclNQfzHUBYF4O0mLxsAbXq68CW1relGtKivrJKz2KcBj2ueOU5ceSQF-0hjvFBMUlyvb5gU5Ozo8PZiFvktDqIHMrcNC1MIIzq2DjmldxonQOSZmZlnJ06KGH4CBw3ZhGNcSPZdRzWWWayOlzpOXZLNpm-o1oZmuDLDkSPISDYuUGbqZeVppWbJM1AHhvX6U9iXMsZPGL9XHqp0rfycUqlVFQoFaAzIdxFauhsd9AlmvfNUnqIJJVTDL3CcobhOsOm8YOsVUF6tIfY8sEI2WDBu9wSUHRA6SHvs4TPM_B93ux6cajjM-LgF5P_wNpgP9QUVTtZe4D5BVwKs8vWMfxjKg6CLmAXnlxv5wDxNcDgPC_ubuE3hLHuPZ2sC8dJtsri8uq3eA5NblDtmY_mE79qGFT3kA21v7x19nc_j-fDhffPsLiqxKYA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NQ3y8IChfhQFGgj0tI0md2HlACA2mlq3TJDrUN5PYjsSEkrJ2Q90fxd_InZ2kPIyNl0mpFKU5JfGdz7_zfQG8zkxscmnQOhnEZcCFDoMsNAJNlSyzRaK5cO6C8UE6POKfp8l0DX63uTAUVtnqRKeoTa1pjxyN9AyRMkqXeD_7GVDXKPKuti00vFjs2eUvNNnm70Yfkb9v4nj302RnGDRdBQKNxsciyEUpjODcOZQirYt4IHRGiYRpWvAkL_ECWox4npuIa0metrDkMs20kVJT8SVU-Tf4AKcmZabv_BVSMnCNRNCs4QGPwukqY-jt8fZZrslVTtFk0tULpfXs4rXwX1jXrXm79-BuA1bZBy9d92HNVj246dtXLntwa9w45nuweehLYC-32GSV0TXfYpvscFUcG2l6Xyn-xiUBs5b8AZyPKkqwOEPga9h33zflPGfNxzAfdNLoZZZXBn94-HIqrC7ZiZ1ZR-spnLQxhOOszVVnPh2TIdxlMY1UJBhtj9bVQzi6Fv49gvWqruwTYKm2Bq3yUPKCFJmUKbm1eWK1LKJUlH3gLX-UbkqmU-eOH6qNjTtWzUgoYqsKhUK29mG7I5v5miFXEaQt81WbEIsqXOGqdhWhuIjQzhtFNFeRmscqVF9CB3zDaUSN5fCT-yA7ygZreQz1Pw_daOVTdc9ZTc8-vOr-RlVF_qe8svUp3YPGMeJjnlxyTxSlWcxFzPvw2Mt-N4YD2n6LZfb08hd4CbeHk_G-2h8d7D2DO_TmLigw2YD1xcmpfY4oclG8cFOXwbfr1hV_AFoegAA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NQ0y8IChfhQFGgj0tW5I6sfOAENqoVsamSmyob15iOxITSsrSDXV_Gn8dd3bS8jA2XialUpTmlMR3Pv_O9wXwNjOxyaVB62QQlwEXOgyy0Ag0VbLMFonmwrkLDg7TvWP-eZJMVuB3lwtDYZWdTnSK2tSa9sjRSM8QKaN0ie2yDYsY7w4_TH8G1EGKPK1dOw0vIvt2_gvNt-b9aBd5_S6Oh5-OdvaCtsNAoNEQmQW5KIURnDvnUqR1EQ-EziipME0LnuQlXkDrEc9zE3EtyesWllymmTZSairEhOr_jhgISXNM7vwVXjJwTUXQxOEBj8LJMnto-3TrItfkNqfIMulqh9LadvW6-C_c69a_4QO43wJX9tFL2kNYsVUP7vpWlvMerB20TvoebIx9Oez5JjtaZnc1m2yDjZeFspGm941icVxCMOvIH8HlqKJkiwsEwYZ99z1ULnPWfgzzASitjmZ5ZfCHhy-twuqSndmpdbSewkkeQ2jOurx15lMzGUJfFtNIRYLRVmldPYbjW-HfE1it6so-A5Zqa9BCDyUvSKlJmZKLmydWyyJKRdkH3vFH6bZ8OnXx-KG6OLlT1Y6EIraqUChkax-2FmRTXz_kJoK0Y77qkmNRnStc4W4iFFcR2qZVSo2KVBOrUH0NHQgOJxE1mcNP7oNcULa4y-Op_3noeiefavGc5VTtw5vF36i2yBeVV7Y-p3vQUEaszJNr7omiNIu5iHkfnnrZX4zhgLbiYpk9v_4FXsMaagn1ZXS4_wLu0Yu7-MBkHVZnZ-f2JQLKWfHKzVwGJ7etKv4AllCENg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inactivated+influenza+vaccine+effectiveness+and+an+analysis+of+repeated+vaccination+for+children+during+the+2016%2F17+season&rft.jtitle=Vaccine&rft.au=Shinjoh%2C+Masayoshi&rft.au=Sugaya%2C+Norio&rft.au=Yamaguchi%2C+Yoshio&rft.au=Iibuchi%2C+Noriko&rft.date=2018-09-05&rft.issn=0264-410X&rft.volume=36&rft.issue=37&rft.spage=5510&rft.epage=5518&rft_id=info:doi/10.1016%2Fj.vaccine.2018.07.065&rft.externalDBID=ECK1-s2.0-S0264410X18310740&rft.externalDocID=1_s2_0_S0264410X18310740 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X18X0036X%2Fcov150h.gif |